They received either sarilumab or adalimumab every 2 weeks. Researchers observed improvements with sarilumab as early as week 4; significantly greater proportions of sarilumab- vs adalimumab-treated ...

PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving ...

Adalimumab is prescribed to treat autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis ...

Review the side-effects of Adalimumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . In a phase 3, randomized, double-blind study, researchers compared the safety and efficacy of biosimilar BI ...

plaque psoriasis The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated. Adding ...

A new, post-hoc study has reported that adalimumab, used as monotherapy, led to positive clinical, functional, and radiographic outcomes in patients with rheumatoid arthritis (RA) for up to 3 years in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adalimumab ...

Please provide your email address to receive an email when new articles are posted on . IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is ...

Bimekizumab bested adalimumab for moderate to severe plaque psoriasis in a phase 3 trial of adults from the agent's maker UCB Pharma. The interleukin-17A (IL-17A) and IL-17F blocker has also racked up ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

The appraisal committee considered evidence submitted by AbbVie and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...